中新集團(601512.SH):擬出資不超8000萬元參投元生蘇州天使二期基金
格隆匯4月18日丨中新集團(601512.SH)公佈,公司擬作為有限合夥人參與投資由蘇州工業園區元生創業投資管理有限公司發起設立的:蘇州工業園區元生天使二期創業投資合夥企業(有限合夥)(簡稱“元生蘇州天使二期基金”),並以現金貨幣方式向標的基金出資不超過8000萬元,且佔比不超過最終基金認繳總額的20%,資金來源為公司自有資金。標的基金採用有限合夥形式設立,規模不低於人民幣4億元且不超過人民幣4.5億元。
基金主要投資於蘇州市工業園區重點聚焦的優勢及新技術產業,具體為:主要投資於新藥創制、醫療器械、體外診斷和醫療服務四大醫療細分領域,尋找針對當前中國未被滿足的臨牀需求及最新科技研發成果轉化。合夥企業存續期間,將識別並扶持工業園區內生物醫療領域新型企業,並引進發展潛力巨大的醫療行業優質企業落地園區,推動工業園區生物醫療產業的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.